openPR Logo
Press release

Deadline on Dec. 7th coming up in Lawsuit filed for Investors in Mesoblast Limited (OTC: MEOBF)

12-02-2020 11:32 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on December 7, 2020  in the lawsuit for certain investors in Mesoblast Limited (OTC: MEOBF).

A Deadline is coming up on December 7, 2020 in the lawsuit for certain investors in Mesoblast Limited (OTC: MEOBF).

A deadline is coming up on December 7, 2020 in the lawsuit filed for certain investors of Mesoblast Limited (OTC: MEOBF) over alleged securities laws violations by Mesoblast Limited (OTC: MEOBF).

Investors who purchased shares of Mesoblast Limited (OTC: MEOBF) have certain options and there are strict and short deadlines running. Deadline: December 7, 2020. OTC: MEOBF stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Mesoblast Limited (OTC: MEOBF) common shares between April 16, 2019 and October 1, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 16, 2019 and October 1, 2020, the Defendants failed to disclose to investors, that comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies, that, as a result, the FDA was reasonably likely to require further clinical studies, that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Mesoblast Limited (OTC: MEOBF) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Dec. 7th coming up in Lawsuit filed for Investors in Mesoblast Limited (OTC: MEOBF) here

News-ID: 2201112 • Views:

More Releases from Shareholders Foundation

Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) shares should contact the Shareholders Foundation
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) s …
An investor, who purchased shares of Stride, Inc. (NYSE: LRN), filed a lawsuit over alleged violations of Federal Securities Laws by Stride, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Stride, Inc. (NYSE: LRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 12, 2026. NYSE: LRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:

All 5 Releases


More Releases for Mesoblast

Regenerative Medicine Platforms Market Is Going to Boom |• Acelity • Organog …
Worldwide Market Reports (WMR) has released a new, in-depth research study on the Regenerative Medicine Platforms Market, projected to witness strong and sustained growth in the coming years. The report delivers a fact-based, strategic analysis of the global market landscape using a robust research framework that integrates market sizing, validated data modeling, and insights drawn from multiple authoritative sources. This study is designed to support executive decision-making, strategic planning, and investment
Regenerative Biotech Solutions Market to Expand Rapidly Over Next Decade| Mesobl …
HTF MI just released the Global Regenerative Biotech Solutions Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Key Players in This Report Include: Mesoblast, Organogenesis, Athersys, Novartis, Gilead,
Regenerative Medicine Market is Booming Worldwide: Organovo, Athersys, Mesoblast
Global Regenerative Medicine Market, is latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Regenerative Medicine Market. Some of the key players profiled in the study are Organovo, Athersys, Mesoblast, Osiris Therapeutics, Stryker, Medtronic, Integra LifeSciences, Thermo
Umbilical Cord Blood (UCB) Stem Cell Market Growth, Industry Research and Develo …
The research reports on the "Umbilical Cord Blood (UCB) Stem Cell Market" report give a detailed overview of the factors affecting the global scope of business. Information in the global Umbilical Cord Blood (UCB) Stem Cell market report provides forecast data for future market growth in global demand and supply. The report initially provides a basic overview of the segments, market dynamics, applications, and technologies in which the report explores
Investigation announced for Investors of Mesoblast Limited (OTC: MEOBF) over pot …
An investigation on behalf of current long-term investors in shares of Mesoblast Limited (OTC: MEOBF) concerning potential breaches of fiduciary duties by certain directors and officers of Mesoblast Limited was announced. Investors who are current long term investors in Mesoblast Limited (OTC: MEOBF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Investigation announced for Investors in shares of Mesoblast Limited (OTC: MEOBF …
An investigation on behalf of investors of Mesoblast Limited (OTC: MEOBF) shares over potential securities laws violations by Mesoblast Limited and certain of its directors and officers in connection with certain financial statements was announced. Investors who purchased shares of Mesoblast Limited (OTC: MEOBF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on